We are delighted to share that Dr. Mirela Sedić has co-authored the paper:
“Quinoline and coumarin isoxazole derivatives: synthesis, antitumor evaluation and molecular docking studies with Bcl-2”, published in RSC Advances (Q1, Impact Factor 4.6).

This study presents the design, synthesis, and biological evaluation of novel quinoline- and coumarin-derived isoxazole analogs (7a–e, 8a–f, 9a–e) and their Re(I) and Ru(II) complexes (7bRe, 9bRe, 7bRu, 9bRu). Among these, compound 8f showed:

  • Low cytotoxicity in healthy peripheral blood mononuclear cells
  • Selective and potent cytostatic activity against pancreatic adenocarcinoma, acute lymphoblastic leukemia, and acute myeloid leukemia  
  • High permeability and moderate clearance rates, which are favorable for oral bioavailability and therapeutic effectiveness.
  • Potential mode of action through Bcl-2 inhibition revealed by molecular docking studies. 
The compound 8f deserves further attention as a promising anti-Bcl-2 lead compound for both solid and hematological malignancies. 
 

Read the full article here: 🔗 https://pubs.rsc.org/en/content/articlehtml/2025/ra/d5ra05483d?page=search

Congratulations to the entire team behind this innovative work!